CAR T Cell Therapy Market

1
Global CAR T Cell Therapy Market is Estimated to
Witness High Growth Owing to Increasing Number of
Cancer Cases and Rising Investments in Cell
Therapy Research

• CAR T Cell Therapy Market
• The global CAR T Cell Therapy market is estimated
  to be valued at USD 2.26 billion in 2022 and is
  expected to exhibit a CAGR of 20.9 over the
  forecast period 2022-2030, as highlighted in a
  new report published by Coherent Market Insights.
• Market Overview
• CAR T Cell Therapy is a type of immunotherapy
  that uses a patient's own genetically modified T
  cells to target and destroy cancer cells. This
  innovative treatment has shown promising results
  in treating various types of cancer, including
  leukemia and lymphoma. CAR T Cell Therapy works
  by engineering T cells to express chimeric
  antigen receptors (CARs) on their surface, which
  enables them to recognize and attack cancer
  cells.
• CAR T Cell Therapy products have gained
  significant attention in recent years due to
  their high efficacy and potential to cure certain
  types of cancers. Companies like Novartis AG,
  Gilead Sciences, and Johnson Johnson are
  investing heavily in CAR T Cell Therapy research
  and development, driving the growth of the
  market.
• Market Dynamics
• 1. Increasing Number of Cancer Cases The global
  prevalence of cancer is on the rise, with
  millions of new cases being diagnosed each year.
  CAR T Cell Therapy offers a promising treatment
  option for patients who have exhausted other
  treatments, leading to increased adoption and
  demand for CAR T Cell Therapy products.

2

• 2. Rising Investments in Cell Therapy Research
  Pharmaceutical companies and research
  institutions are investing heavily in cell
  therapy research, with a specific focus on CAR T
  Cell Therapy. This investment is driving the
  development of new products and technologies in
  the market, further fueling market growth.
• C) Segment Analysis
• The CAR T Cell Therapy market can be segmented
  based on target antigen, application, and end-
  user. The CD19 segment dominates the market, as
  CD19 is a common antigen found on cancer cells in
  various types of lymphomas and leukemias.
  Additionally, the oncology segment is the leading
  application for CAR T Cell Therapy, as it is
  primarily used for the treatment of various types
  of cancers.
• PEST Analysis
• Political Governments worldwide are increasing
  their focus on improving cancer care and
  treatment, creating favorable policies and
  regulations for the development and adoption of
  innovative therapies like CAR T Cell Therapy.
• Economic The high cost of CAR T Cell Therapy and
  the need for specialized manufacturing facilities
  pose economic challenges. However, the market is
  expected to grow due to increasing investments in
  research and development.
• Social The growing awareness and acceptance of
  CAR T Cell Therapy among patients and healthcare
  professionals are driving market growth.
  Additionally, the rising burden of cancer
  globally is creating a demand for effective
  treatment options.
• Technological Advances in genetic engineering
  and cell therapy technologies are enabling the
  development of more efficient and targeted CAR T
  Cell Therapy products. These advancements are
  expected to drive market growth.
• Key Takeaways
• The global CAR T Cell Therapy market is expected
  to witness high growth, exhibiting a CAGR of
  20.9 over the forecast period, due to increasing
  cases of cancer and rising investments in cell
  therapy research.
• North America is the fastest-growing and
  dominating region in the CAR T cell therapy
  market, driven by extensive research activities
  and early adoption of innovative therapies.
• Key players operating in the global CAR T Cell
  Therapy market include Fate Therapeutics, Mustang
  Bio, Sorrento Therapeutics, Inc., Bluebird bio,
  Inc., Pfizer Inc., Gilead Sciences, Inc., Legend
  Biotech, Aurora Biopharma, CARsgen Therapeutics
  Co., Ltd, Novartis AG, Johnson Johnson
  Services, Inc., and Bristol-Myers Squibb Company.
  These companies are investing in research and
  development to bring innovative CAR T Cell
  Therapy products to the market.